Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with ...

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks ...

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Regulators have set a goal of Aug. 12, 2025, for brensocatib to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung disease. The FDA has accepted Insmed’s new drug application for ...

PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still ...

Study results show that genetic sensitivity to stress was linked to a 49% higher risk of lung cancer in people of European ...

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

Two-thirds of high severity likely due to upcoding, according to a RAND study of hospitalizations in five states. Upcoding is one of the biggest bones of contention between U.S. payers and providers, ...

COUR Pharmaceuticals is about begin a phase 1b/2a study to assess a therapy for type 1 diabetes that prevents islet cell destruction and triggers a T cell response.